Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
复制标题
DOI：
10.1158/1078-0432.ccr-16-2981
复制
发表时间：
2017-08-01
影响因子：
11.5
通讯作者：
Schaap, Nicolaas M.
中科院分区：
文献类型：
--
作者：
Dolstra, Harry;Roeven, Mieke W. H.;Schaap, Nicolaas M.
目的：老年急性髓细胞白血病（AML）患者预后差，因此需要新的治疗方法。同种异体自然杀伤（NK）细胞已被过继转移，具有良好的临床效果。在这里，我们报告了第一个非人研究，利用从部分HLA匹配的脐带血单位的CD 34（+）造血干细胞和祖细胞（HSPC）离体产生的独特的可扩展NK细胞产物。10例形态学完全缓解的老年AML患者接受了递增的HSPC-NK细胞剂量结果：HSPC-NK细胞产品含有中位数为75%的高活化NK细胞，
Purpose: Older acute myeloid leukemia (AML) patients have a poor prognosis; therefore, novel therapies are needed. Allogeneic natural killer (NK) cells have been adoptively transferred with promising clinical results. Here, we report the first-inhuman study exploiting a unique scalable NK-cell product generated ex vivo from CD34(+) hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.Experimental Design: Ten older AML patients in morphologic complete remission received an escalating HSPC-NK cell dose (between 3 and 30 x 10(6)/kg body weight) after lymphodepleting chemotherapy without cytokine boosting.Results: HSPC-NK cell products contained a median of 75% highly activated NK cells, with